scholarly article | Q13442814 |
P356 | DOI | 10.1161/01.ATV.15.9.1263 |
P953 | full work available at URL | https://www.ahajournals.org/doi/full/10.1161/01.ATV.15.9.1263 |
P698 | PubMed publication ID | 7670937 |
P2093 | author name string | A. Simon | |
J. Levenson | |||
P. Giral | |||
J. Gariepy | |||
M. Razavian | |||
P2860 | cites work | The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 |
The New England Journal of Medicine | Q582728 | ||
Increase in erythrocyte disaggregation shear stress in hypertension | Q33230945 | ||
Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study | Q33612628 | ||
Fibrinogen: a possible link between social class and coronary heart disease | Q34488611 | ||
Atherosclerosis and the coagulation system | Q38713518 | ||
Role of endothelium in sequestration of lipoprotein and firbrinogen in aortic lesions, thrombi, and graft pseudo-intimas | Q39568898 | ||
Fibrinogen and low density lipoprotein in the development of cerebral atherosclerosis | Q40279327 | ||
Insoluble "fibrin" in human aortic intima. Quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoprotein | Q40302035 | ||
Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature | Q40904739 | ||
Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations | Q41887737 | ||
Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies | Q43950275 | ||
Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. | Q44082955 | ||
Genetic and cultural inheritance of plasma fibrinogen concentration | Q47391741 | ||
Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
Relation between extent of coronary artery disease and blood viscosity. | Q54965703 | ||
Fibrinogen, factor VII clotting activity and coronary artery disease severity | Q67255139 | ||
Hypercholesterolaemia alters arterial and blood factors related to atherosclerosis in hypertension | Q67569162 | ||
Fate of fibrinogen in human arterial intima | Q68735946 | ||
Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis | Q69662969 | ||
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
Risk factors in middle age that predict early and late onset of coronary heart disease | Q69949126 | ||
Risk factors and early extracoronary atherosclerotic plaques detected by three-site ultrasound imaging in hypercholesterolemic men. Prévention Cardio-vasculaire en Médecine du Travail METRA Group | Q70145901 | ||
Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration | Q70782550 | ||
Haemostatic function and cardiovascular death: early results of a prospective study | Q72423400 | ||
Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic disease | Q72639026 | ||
Longitudinal associations between plasma viscosity and cardiovascular risk factors in a middle-aged French population | Q72672917 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1263-1268 | |
P577 | publication date | 1995-09-01 | |
P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
P1476 | title | Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors | |
Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors | |||
P478 | volume | 15 |
Q43787052 | A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study |
Q42837232 | Association between laboratory markers and presence of coronary artery disease |
Q43919582 | Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). |
Q74137858 | Association of plasma viscosity and carotid thickening in a French working cohort |
Q38439938 | Association of serum immunoglobulin-G to Porphyromonas gingivalis with acute cerebral infarction in the Chinese population |
Q33729553 | Clinical correlation between N-terminal pro-B-type natriuretic peptide and angiographic coronary atherosclerosis |
Q33911689 | Control of fibrinogen biosynthesis: role of the FFA/albumin ratio |
Q36708368 | Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT) |
Q35802635 | Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia |
Q24793954 | Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes |
Q54129425 | Erythrocyte antioxidant status in asymptomatic hypercholesterolemic men. |
Q34100016 | Erythrocyte, but not plasma, vitamin E concentration is associated with carotid intima-media thickening in asymptomatic men at risk for cardiovascular disease |
Q33738532 | Expanded network of inflammatory markers of atherogenesis: where are we now? |
Q73637155 | Fibrinogen is an efficient antioxidant |
Q50907848 | Fibrinogen is an independent marker for thoracic aortic atherosclerosis. |
Q35538771 | Fibrinogen: biochemistry, epidemiology and determinants |
Q75319402 | Impaired fibrinolytic activity is present in children with dyslipidemias |
Q37149080 | Iron-induced fibrin in cardiovascular disease |
Q43850656 | Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib. |
Q34310277 | Pathophysiology of oxidative stress in diabetes mellitus |
Q41560071 | Pharmacological approaches and strategies for therapeutic modulation of fibrinogen |
Q73022835 | Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude |
Q35610165 | Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1. |
Q28369047 | Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease |
Q35024896 | Stress and the inflammatory response: a review of neurogenic inflammation |
Q34500682 | Stress, inflammation and cardiovascular disease |
Q73644431 | Study of vitamin E net mass transfer between alpha-tocopherol-enriched HDL and erythrocytes: application to asymptomatic hypercholesterolemic men |
Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
Q56891683 | Vasoactive effects of fibrinogen on saphenous vein |
Q37022169 | What's going on in LDL apheresis |